Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Accendra Health's Sloan Ratio for the quarter that ended in Mar. 2026 was -50.16%.
Warning Sign:
When sloan ratio (-46.63)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.
As of Mar. 2026, Accendra Health has a Sloan Ratio of -50.16%, indicating earnings are more likely to be made up of accruals.
Accendra Health (NYSE:ACH) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2026, Accendra Health has a Sloan Ratio of -50.16%, indicating earnings are more likely to be made up of accruals.
Accendra Health Sloan Ratio % Related Terms
Accendra Health Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Accendra Health's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Accendra Health's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accendra Health Sloan Ratio % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Accendra Health's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Accendra Health's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Accendra Health's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
Accendra Health's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was -869.058 (Jun. 2025 ) + -150.276 (Sep. 2025 ) + -56.326 (Dec. 2025 ) + -6.468 (Mar. 2026 ) = $-1,082 Mil.
Accendra Health's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was 37.61 (Jun. 2025 ) + -172.52 (Sep. 2025 ) + 68.186 (Dec. 2025 ) + -50.077 (Mar. 2026 ) = $-117 Mil.
Accendra Health's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 was -52.917 (Jun. 2025 ) + -39.464 (Sep. 2025 ) + 285.004 (Dec. 2025 ) + 53.925 (Mar. 2026 ) = $247 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accendra Health (ACH) has a Sloan Ratio % of -50.16% as of Mar. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Accendra Health and its competitors.
Is Accendra Health's Sloan Ratio % too high?
Accendra Health's current Sloan Ratio % is -50.16%. Overall, Accendra Health has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Accendra Health's Sloan Ratio % compare to FOCL and YI?
Accendra Health's Sloan Ratio % of -50.16% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Medical Distribution company?
A good Sloan Ratio % depends on the Medical Distribution industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Accendra Health and its competitors. Accendra Health's current Sloan Ratio % is -50.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accendra Health stock overvalued right now?
Based on GuruFocus' analysis, Accendra Health (ACH) is currently considered Possible Value Trap. The stock's GF Value™ is $5.44, compared to a current price of $3.14 — trading 42.3% below its estimated fair value. The current Sloan Ratio % is -50.16%. Accendra Health's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Accendra Health (ACH), the current Sloan Ratio % is -50.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Accendra Health (ACH) Overvalued in 2026?
Based on GuruFocus' analysis, Accendra Health stock appears to be undervalued.
The current stock price of $3.14 is trading 42.3% below its estimated GF Value™ of $5.44.
GuruFocus considers Accendra Health to be Possible Value Trap.
Key valuation signals for ACH:
Sloan Ratio %: -50.16%
GF Value™: $5.44 vs. price of $3.14 (42.3% below fair value)
No single metric tells the full story. See the ACH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services. The company also supplies a broad range of home medical equipment and patient care products, including ostomy, wound care, urology, and incontinence solutions.
59GF Score
Get the complete analysis for ACH
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACH has been successfully added to your 
